Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival

Circulation Journal

Volumn 74, Issue 7, 2010, Pages 1364-1371

  Tsuchihashi Makaya, Miyuki ^a   Kinugawa, Shintaro ^a   Yokoshiki, Hisashi ^a   Hamaguchi, Sanae ^a   Yokota, Takashi ^a   Goto, Daisuke ^a   Goto, Kazutomo ^a   Takeshita, Akira ^b   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Saiseikai Futsukaichi Hospital   (Japan)

Author keywords

Heart failure; Outcome; Re admission; Survival; blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK REDUCTION; SURVIVAL; TREATMENT OUTCOME; HEART VENTRICLE FUNCTION; HOSPITALIZATION; INFORMATION PROCESSING; MIDDLE AGED; SURVIVAL RATE; SURVIVOR; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DATA COLLECTION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; SURVIVAL RATE; SURVIVORS; VENTRICULAR DYSFUNCTION;

EID: 77954484555     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0993     Document Type: Article

References (24)

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
3. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
5. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
6. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, et al. Contemporary management of patients with left ventricular systolic dysfunction: Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20: 1182-1190.
7. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
8. Gattis WA, O'Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol 2004; 93: 74B-76B.
9. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43: 1534-1541.
10. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007; 153: 82 e1-e11.
11. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Influence of β-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52: 190-199.
12. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 2006; 70: 1617-1623.
13. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Ide T, Takeshita A, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1442-1447.
14. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
15. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan: A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-1908.
16. Joffe MM, Rosenbaum PR. Invited commentary: Propensity scores. Am J Epidemiol 1999; 150: 327-333.
17. Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12: e1-e2.
18. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005; 294: 1240-1247.
19. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The Euro Heart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment. Eur Heart J 2003; 24: 464-474.
20. Komajda M, Hanon O, Hochadel M, Follath F, Swedberg K, Gitt A, et al. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J 2007; 28: 1310-1318.
21. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002; 360: 1631-1639.
22. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of β-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-192.
23. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-blockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med 2002; 137: 715-725.
24. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardi-oselective β-blockers for chronic obstructive pulmonary disease: A meta-analysis. Respir Med 2003; 97: 1094-1101.